[Surgery alone or in association with preoperative uterovaginal brachytherapy for stage IB1 cervical cancer: Toxicities profiles].

Date publication

mai 2015

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MARTIN Etienne , Dr ROUFFIAC-THOUANT Magali

Tous les auteurs :
Lamblin G, Rouffiac M, Mathevet P, Martin E, Peignaux-Casasnovas K, Chabert P, Lebail-Carval K, Chene G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25986397

Résumé

OBJECTIVE: To assess toxicity profile in two stage-IB1 cervical cancer treatment strategies: surgery with and without preoperative uterovaginal pulsed dose-rate brachytherapy. METHODS: A retrospective study included 45 patients presenting stage-IB1 cervical cancer without pelvic lymph-node invasion, between 2009 and 2011: 25 treated by colpohysterectomy alone (group A) and 20 with preoperative uterovaginal pulsed dose-rate brachytherapy (group B). The median follow-up was 45 and 39 months (group A and B). RESULTS: Groups were comparable for age (median, 46.9 vs 47.6 years), histologic type (52% vs 65% squamous cell carcinoma) and tumor size (68% vs 60%,

Référence

Gynecol Obstet Fertil. 2015 May 15. pii: S1297-9589(15)00122-8